Literature DB >> 26378998

Usage and usability of one dry powder inhaler compared to other inhalers at therapy start: an open, non-interventional observational study in Poland and Germany.

Piotr Hantulik1, Karola Wittig, Yvonne Henschel, Joachim Ochse, Mikko Vahteristo, Paula Rytila.   

Abstract

INTRODUCTION: Inhalation is the preferred route of drug administration for patients with asthma or COPD. It is generally predicted that there is a high error rate in inhaler usage, especially at the therapy start. The primary objective of this study was the validation of a questionnaire that can be used for assessing a successful inhalation technique, patient satisfaction as well as the compliance in daily practice.The secondary objective was to examine the "real-life" usage of one inhalation device in comparison with other devices at the start of the therapy.
MATERIAL AND METHODS: This open, multi centre and non-interventional study was designed to examine usage and usability of dry powder inhaler Easyhaler® (EH) (Orion Pharma, Finland) and other inhalers assessed by the physicians as well as by the patients. Inclusion criteria for patients were a physician-diagnosis of COPD or asthma or children with asthmatic disease, therapy start with an inhalation device and no or only few experiences with inhaler usage (inhaler usage for not more than 3 months). Each physician enrolled an equal number of patients in each group.
RESULTS: 263 adult/adolescent patients with asthma and 115 with COPD as well as 164 children with asthmatic disease were enrolled. 49.4% of the adult/adolescent patients with asthma used an EH and 50.6% other inhalers. In the case of COPD, 47.8% were treated with an EH and 52.2% used other inhalation devices. Finally, 50.6% of the children with asthmatic disease used an EH and 49.4% were treated with other inhalers. Inhaler usage, patient satisfaction, compliance and patients assessments of usability were better when the patients used an EH. Inconvenient features were mainly documented for other inhalers. The analysis of Cronbachs alpha clearly showed the consistency of the received data from all patients. In addition, there was a large association between the assessment of the inhaler usage and the general assessment of the used inhaler in all patient groups.
CONCLUSION: The results of this study show that investigators found EH easy to teach, the patients found it easy to use and their satisfaction with the device was high in comparison to other inhalation devices. Thus EH can be matched to many patients already at the therapy start. In addition, the high consistency of the received data and large association of the assessment of the inhaler usage and the general assessment of the inhaler indicate that the used questionnaires were appropriate tools to examine usage and usability of inhaler devices in adult patients and children.

Entities:  

Keywords:  Asthma; COPD; DPI; Easyhaler®; adherence; inhalation therapy; patient compliance

Mesh:

Substances:

Year:  2015        PMID: 26378998     DOI: 10.5603/PiAP.2015.0059

Source DB:  PubMed          Journal:  Pneumonol Alergol Pol        ISSN: 0867-7077


  8 in total

1.  The Global Usability Score Short-Form for the simplified assessment of dry powder inhalers (DPIs) usability.

Authors:  Massimiliano Povero; Paola Turco; Luca Bonadiman; Roberto W Dal Negro
Journal:  Multidiscip Respir Med       Date:  2020-07-21

2.  In Vitro Flow Rate Dependency of Delivered Dose and Fine Particle Dose of Salmeterol/Fluticasone Propionate Easyhaler and Seretide Diskus with Patient Flow Rates Collected in a Randomized Controlled Trial.

Authors:  Rain Jõgi; Satu Lähelmä; Mikko Vahteristo; Anita Happonen; Jussi Haikarainen
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2018-10-09       Impact factor: 2.849

3.  Clinical Effectiveness of Budesonide/Formoterol Fumarate Easyhaler® for Patients with Poorly Controlled Obstructive Airway Disease: a Real-World Study of Patient-Reported Outcomes.

Authors:  Lilla Tamási; Maria Szilasi; Gabriella Gálffy
Journal:  Adv Ther       Date:  2018-07-31       Impact factor: 3.845

4.  A Multicenter, Observational, Prospective Study of the Effectiveness of Switching from Budesonide/Formoterol Turbuhaler® to Budesonide/Formoterol Easyhaler®.

Authors:  Jörgen Syk; Ines Vinge; Mikael Sörberg; Mikko Vahteristo; Paula Rytilä
Journal:  Adv Ther       Date:  2019-04-02       Impact factor: 3.845

5.  Evaluation of the Efficiency of Single-Inhaler Combination Therapy with Budesonide/Formoterol Fumarate in Patients with Bronchial Asthma in Daily Clinical Practice.

Authors:  Michał Pirożyński; Piotr Hantulik; Agnieszka Almgren-Rachtan; Jerzy Chudek
Journal:  Adv Ther       Date:  2017-11-08       Impact factor: 3.845

6.  Dose uniformity of budesonide Easyhaler® under simulated real-life conditions and with low inspiration flow rates.

Authors:  Jussi Haikarainen; Paula Rytilä; Sirkku Roos; Sirpa Metsärinne; Anita Happonen
Journal:  Chron Respir Dis       Date:  2017-12-07       Impact factor: 2.444

7.  Patients' usability of seven most used dry-powder inhalers in COPD.

Authors:  Roberto W Dal Negro; Paola Turco; Massimiliano Povero
Journal:  Multidiscip Respir Med       Date:  2019-09-13

8.  Design and Characterizations of Inhalable Poly(lactic-co-glycolic acid) Microspheres Prepared by the Fine Droplet Drying Process for a Sustained Effect of Salmon Calcitonin.

Authors:  Hideyuki Sato; Aiko Tabata; Tatsuru Moritani; Tadahiko Morinaga; Takahiro Mizumoto; Yoshiki Seto; Satomi Onoue
Journal:  Molecules       Date:  2020-03-13       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.